Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253310 | 0.87 | MAPT (0.63) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL8232713 | 0.85 | MAPT (0.61) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL13171438 | 0.83 | MAPT (0.58) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3156176 | 0.83 | MAPT (0.58) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL16639876 | 0.83 | MAPT (0.58) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23918440 | 0.83 | MAPT (0.58) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL6320904 | 0.83 | MAPT (0.62) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL6321844 | 0.81 | MAPT (0.52) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23175746 | 0.81 | KDM4E (0.49) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL23175748 | 0.81 | KDM4E (0.49) | KDM4EMAPTKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530094-B1 | Organophotoreceptor with charge transport material having three arylamino groups | SAMSUNG ELECTRONICS CO LTD (KR) | 2007-02-28 | — | — | EP | disclosed |
| US-7132209-B2 | Organophotoreceptor with charge transport material having three arylamino groups | SAMSUNG ELECTRONICS CO., LTD (KR) | 2006-11-07 | — | — | US | disclosed |
| EP-1530094-A2 | Organophotoreceptor with charge transport material having three arylamino groups | Samsung Electronics Co., Ltd. (KR) | 2005-05-11 | — | — | EP | disclosed |
| US-20050095518-A1 | photoconductive element with bis(hydrazone) carbazole compounds of given formula as charge transport material; electrophotographic apparatus and imaging method; good electrostatic properties | S-PRINTING SOLUTION CO., LTD. (KR) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095518-A1 | photoconductive element with bis(hydrazone) carbazole compounds of given formula as charge transport material; electrophotographic apparatus and imaging method; good electrostatic properties | CHRM5, NR2E3, CHRM3 | KDM4E 2949/4885MAPT 3367/4885KMT2A 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.